Lithium and Acetate for Canavan Disease

• Status: Withdrawn
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: European Leukodystrophy Association
• Treatments: Lithium Carbonate; Triacetin

Criteria

Inclusion Criteria:

• Clinical and biochemical diagnosis of Canavan disease

Exclusion Criteria:

• Renal disease

• Thyroid disease

• Cardiac disease

• Impossibility to perform brain MRI